Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734044 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL5800570 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL23962341 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL967471 | 0.80 | SMN1; SMN2 (0.54) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL968486 | 0.75 | HTT (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL8391822 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL8392707 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL24059132 | 0.75 | MMP1 (0.45) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL5824896 | 0.75 | CA12 (0.43) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL2677860 | 0.75 | ALDH1A1 (0.48) | SMN1; SMN2CA12CA1CA9TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | claimed |
| JP-2009538338-A | — | — | 2009-11-05 | — | — | JP | claimed |
| EP-2019690-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU'S REACTION | Elan Pharmaceuticals Inc. (US) | 2009-02-04 | — | — | EP | claimed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007137260-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| CN-117534670-A | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-3697784-B9 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-12-27 | — | — | EP | disclosed |
| CN-111225916-B | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | 加拉帕戈斯股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4265254-A2 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2023-10-25 | — | — | EP | disclosed |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-05 | — | — | US | disclosed |
| EP-3697784-B1 | IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-10-04 | — | — | EP | disclosed |
| CN-106470985-A | Indane and indoline derivatives as soluble guanylate cyclase activators and uses thereof | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| WO-2016001875-A1 | INDANE AND INDOLINE DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2019690-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU'S REACTION | Elan Pharmaceuticals Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007137260-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1518536-A9 | Composition for oxidative hair treatment and process for permanent hair shaping | Wella Aktiengesellschaft (DE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1518536-A2 | Composition for oxidative hair treatment and process for permanent hair shaping | Wella Aktiengesellschaft (DE) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | PIGO, MANBA, OAT | SMN1; SMN2 1142/4885CA12 1118/4885CA1 1845/4885 |
| US-20230310433-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL15, IL2, IL33 | SMN1; SMN2 3211/4885CA12 228/4885CA1 3364/4885 |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | SMN1; SMN2 3211/4885CA12 228/4885CA1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.